In January, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama's handling of the generic biotech issue, will be the defining issue of 2009 and beyond.
by Dr. Paul Stoffels, the company group chairman of pharmaceutical research and development at Johnson & Johnson
Collaborative innovation for the post-crisis world
LAST WEEK, world and business leaders converged at Davos to wrestle
with the global economic crisis and discuss solutions for "Shaping the
Post-Crisis World" in six areas, including economics, politics,
innovation, science, technology, and new business models. As a
physician, a pharmaceutical research and development business leader,
and a global citizen, I see one major road to economic recovery and
that is through innovation.
Proposals advocating "open" or "collaborative" innovation in pharma
R&D are suddenly cropping up throughout the pharma industry in a
variety of forums and iterations. J&J's head of global R&D Paul
Stoffels talks about it, as does GlaxoSmithKline's Andrew Witty. Not
that collaboration itself is news - business development is a mainstay
of pharma strategy.
Genentech/Merck Serono: is this the end of the line for Raptiva?
Raptiva's safety profile continues to face US and EU regulatory agency scrutiny, which Datamonitor believes will have significant ramifications for the drug's use in psoriasis and any future employment in transplantation. With fresh concern over the safety of Genentech's drug, alternative therapies are likely to impact upon Raptiva's commercial potential.
GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK lost its position as market leader to Gilead in 2007. The new collaboration with Idenix will, however, help the company to maintain its share in the fiercely competitive HIV market.
Technology Platform Offers Tested Solution to Fungal Care Market
HemCon Medical Technologies today announced
preliminary data resulting from an independent study to
treat Onychomycosis, a
common fungal nail infection. The studies were conducted using a
formulation based on HemCon's newest proprietary platform technology
available for license, MycosinateTM (formerly known as
A31S), that provides a controlled release broad spectrum antifungal and
antibacterial agent to fight infection.
Now you can improve your Internet popularity by exchanging links with Farmavita.Net.
One of the main aspects of search engine optimization is link popularity, which is determined by the number of links from other sites that point to a site; more quality links brings better popularity.
Don’t Need Quality Patent Information? Think Again…
Sydney, Australia 29th September, 2008. A recent case heard in the Federal Court of Australia illustrates the need for comprehensive, accurate and regularly updated patent information to ensure that the planned launch of a generic pharmaceutical product is not delayed.
Farmavita.Net Journal 
Biosimilars in the EU: delivering the goods?
Share your links with Farmavita.Net 
